ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: Is there a correlation with disease status?

Lupus

Volumn 22, Issue 5, 2013, Pages 443-452

  Klonizakis, P ^a   Tselios, K ^a   Sarantopoulos, A ^a   Gougourellas, I ^a   Rouka, E ^b   Onufriadou, Z ^c   Kapali, P ^c   Kyriakou, D ^b   Boura, P ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

ADAMTS 13; cumulative tissue damage; disease activity; systemic lupus erythematosus; thrombosis

Indexed keywords

AUTOANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ADAM PROTEINS; ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; DOWN-REGULATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84875957642     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313477898     Document Type: Article

References (31)

1. Kwok S, Ju J, Cho C, Kim H, Park S. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: A single centre study. Lupus. 2009 ; 18: 16-21
2. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004 ;: 407-423
3. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004 ; 103: 4043-4049
4. Tsai H-M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010 ; 91: 1-19
5. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005 ; 15: 302-308
6. Letchumanan P, Ng H-J, Lee L-H, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009 ; 48: 399-403
7. Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: The role of ADAMTS13. Rheumatology. 2010 ; 50: 824-829
8. Al-Awadhi AM, Jadaon MM, Al-Jafar HA, Al-Wazzan HJ. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait. Acta Haem. 2011 ; 125: 160-166
9. Lancellotti S, De Filippis V, Pozzi N, et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 2010 ; 48: 446-456
10. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010 ; 115: 706-712
11. Thachil J. Thrombotic thrombocytopenic purpura: Is there more than ADAMTS-13?. J Thromb Haemost. 2007 ; 5: 634-635
12. Musial J, Swadzba J, Szczeklik A. Adaptive mechanisms counterbalancing enhanced thrombinogenesis in antiphospholipid syndrome. Thromb Res. 1998 ; 90: 93-94
13. Yamazaki M, Asakura H, Jokaji H, et al. Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost. 1994 ; 71: 424-427
14. Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009 ; 102: 371-378
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
17. Soejima K. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003 ; 102: 3232-3237
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
19. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369
20. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol. 2000 ; 27: 1892-1895
21. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials. J Rheumatol. 1998 ; 25: 277-284
22. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 ; 67: 195-205
23. Matrat A, Veysseyre-Balter C, Trolliet P, et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus. 2011 ; 20: 28-34
24. Dayal NA, Gordon C, Tucker L, Isenberg DA. The SLICC damage index: Past, present and future. Lupus. 2002 ; 11: 261-265
25. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
26. Liu F, Feys HB, Dong N, Zhao Y, Ruan C. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Thromb Haemost. 2006 ; 95: 749-750
27. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005 ; 106: 1262-1267
28. Mannucci PMVM, Forza I, Teresa CM, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue disases (systemic lupus erythematosus and systemic sclerosis). Haematologica. 2003 ; 88: 914-918
29. Austin SK, Starke RD, Lawrie AS, Cohen H, Machin SJ, Mackie IJ. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol. 2008 ; 141: 536-544
30. Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost. 2008 ; 6: 1233-1235
31. Hunt B. Microangiopathic haemolytic anaemias in systemic lupus erythematosus. Lupus. 2009 ; 18: 1028-1028